• Bespak to offer nasal dry powder delivery device under MOU with SNBL

  CDMO Bespak, which recently said that it had partnered with Upperton to offer nasal drug/device development and manufacturing and launched a new soft mist intranasal delivery device, has announced that it will now offer access… [Read more . . .]

• Lupin launches Formoflo-G glypocyrronium / formoterol / fluticasone MDI for the treatment of COPD in India

  Lupin has announced the approval of its Formoflo-G glypocyrronium / formoterol / fluticasone propionate MDI for the treatment of COPD by the Drug Controller General of India (DCGI) and the subsequent launch of the inhaler… [Read more . . .]

• Liquidia to submit sNDA to remove PH-ILD indication from Yutrepia treprostinil DPI after court finds that it infringes claims in United Therapeutics patent covering Tyvaso

  A judge in the United States District Court for the District of Delaware has found infringement by Liquidia of two claims included in US Patent No. 11,826,327 (“Treatment for interstitial lung disease”), which was issued… [Read more . . .]

• Bespak launches its new NasaDose Ultra Soft Unit Dose Spray nasal delivery device

  CDMO Bespak, which recently announced a collaboration with Upperton to offer complete nasal drug/device development and manufacturing services, has now announced the launch of a new soft mist nasal delivery device called NasaDose Ultra Soft Unit… [Read more . . .]

• Nasus Pharma initiates Phase 1 trial of NS003 intranasal dry powder ondansetron

  Nasus Pharma has announced the initiation of a Phase 1 PK study of its NS003 nasal powder ondansetron, which the company is developing for the treatment of nausea and vomiting following surgical procedures or chemotherapy.… [Read more . . .]

• Mosanna Therapeutics says data from Phase 1 trial of MOS118 nasal spray in healthy volunteers supports advancement into patients with sleep apnea

• Tiziana initiates Phase 2a BANYAN trial of intranasal foralumab in patients with ALS

• Kither Biotech initiates Phase 1b/2a trial of KIT2014 inhaled PDE3/4 inhibitor in COPD patients

• Harro Höfliger announces availability of commercial scale dry-filling technology for MDIs

• Macquarie University research project on formulation of inhaled dry powder biologics will involve Aptar Pharma’s Orbital DPI

More news . . .